Arrowstreet Capital’s CureVac CVAC Stock Holding History

Arrowstreet Capital’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-150,428	Closed	-$810K	–	1865
2025 Q3	$810K	Buy	+150,428	New	+$814K	﹤0.01%	1636
2022 Q1	–	Sell	-16,317	Closed	-$560K	–	1254
2021 Q4	$560K	Sell	16,317 -198,824	-92%	-$8M	﹤0.01%	1268
2021 Q3	$11.8M	Buy	215,141 +92,030	+75%	+$5.55M	0.01%	693
2021 Q2	$9.05M	Buy	+123,111	New	+$12.3M	0.01%	873

Other funds holding CVAC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Arrowstreet Capital's CVAC Position: Q4 2025 in Review

Arrowstreet Capital sold out of CureVac (CVAC) in Q4 2025, closing a stake of 150,428 shares — an estimated $810K sold.

Arrowstreet Capital first reported a position in CVAC in Q2 2021 and held it in 4 quarters. The position peaked at $11.8M in Q3 2021. 57 funds tracked by Wall St. Rank hold CVAC as of Q4 2025.

Arrowstreet Capital reported no remaining CureVac position as of Q4 2025 after selling out during the quarter.
Arrowstreet Capital sold 150,428 CureVac shares in Q4 2025, an estimated $810K.
Arrowstreet Capital first reported a position in CureVac in Q2 2021 and held it in 4 quarters.
Arrowstreet Capital's CureVac position peaked at $11.8M in Q3 2021.
57 funds tracked by Wall St. Rank held CureVac as of Q4 2025.

Based on Arrowstreet Capital's 13F filing for Q4 2025, filed 13 Feb 2026.